Abstract: Disclosed herein are compounds according to Formula I. (I). Compounds according to Formula I inhibit PKMYT1 and are useful for the treatment of cancer and other disease. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Abstract: Disclosed are systems and methods for assessing driving risk in the field of vehicle telematics. The disclosed technology addresses the challenge of evaluating risk from raw, irregularly sampled telematics time series. The system comprises at least one data storage for telematics data and at least one processor operable to determine velocity vectors, longitudinal acceleration, and lateral acceleration from geospatial data, identify trip subintervals with non-zero speed events, and detect anomalous trip events using a stochastic model, such as a continuous-time hidden Markov model. The processor flags events exceeding a threshold as anomalous. A trip risk score is calculated based on the proportion of anomalous events. Principal uses include insurance premium adjustment, fleet management, and driver coaching. The disclosed technology further encompasses processes and non-transitory computer-readable media for implementing these functionalities.

Abstract: A data processing apparatus may be included in a combined processing apparatus as a computing apparatus. The combined processing apparatus may further include an interface apparatus and other processing apparatus. The computing apparatus interacts with other processing apparatus to jointly complete a computing operation specified by a user. The combined processing apparatus may further include a storage apparatus. The storage apparatus is connected to the computing apparatus and other processing apparatus, respectively. The storage apparatus is configured to store data of the computing apparatus and other processing apparatus. The solution optimizes a convolution operation of a multi-dimensional array and improves operation processing efficiency.

Abstract: A system and method of detecting mobile devices is provided. The method comprises a processor sending a soft page message via MSISDN to an MME, tracking at least one of a TMSI, S-TMSI, GUTI, or c-RNTI, and receiving a P-RNTI filtering message from an eNB. A system and method of classifying detected mobile devices is also provided. The method comprises listening on an uplink channel for a detected mobile device, receiving from the detected mobile device capabilities information regarding the detected mobile device, and obtaining a UE model of the detected mobile device where the UE model is determined based on the capabilities information.

Abstract: The present application relates to the technical field of biomembranes and, in particular, to a method for extracting an exosome. The method for extracting an exosome includes the following steps: step 1. adding a whole blood sample onto a microfluidic centrifuge disk; step 2. separating the whole blood to obtain plasma; step 3. filtering the plasma with a microfiltration membrane; step 4. mixing the filtered plasma with a loading solution to obtain a mixed solution; step 5. filtering the mixed solution with a surface-modified membrane to trap the exosome on the surface-modified membrane; and step 6. eluting the exosome from the surface-modified membrane to obtain a target exosome.

Abstract: Systems, apparatuses and methods may provide for technology that determines a ratio of floating point instructions to memory read instructions and controls a dimension size of a matrix kernel based at least in part on the ratio. In one example, the matrix kernel conducts an operation between a first matrix and a second matrix and the technology reuses elements of the first matrix for multiple vector lines of the second matrix.

Abstract: The invention provides compounds of Formula (I), as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

Abstract: A plurality of beacons that do not include any service set identifiers may be broadcast from an access point. A request concerning association with the access point may be sent wirelessly from a user device and received at the access point. A unique service set identifier (SSID) for the requesting user device may be generated, and information regarding the unique SSID may be transmitted to the requesting user device. A subsequent association request from the requesting user device may include the unique SSID.

Abstract: The present invention provides a method for removing pentavalent antimony contaminants in water without adding a DC power supply and also provides a fuel cell capable of removing the pentavalent antimony contaminants in water by utilizing self-generated electric energy. A technical solution of the present invention is as follows: waste water is pumped into a reactor for reaction after a pH value of the waste water containing the pentavalent antimony contaminants adjusted to 3-6.5; the inside of a reactor is an anaerobic environment; and an iron anode is arranged in the reactor, a through hole is formed in a side wall of the reactor, a cathode for reducing oxygen by electrons and protons sealed and inlaid in the through hole, and a resistor is connected between the iron anode and the cathode in series. The present invention is suitable for a water treatment technology.

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

Abstract: Methods and apparatus relating to seamless host system gesture experience for guest applications on touch based devices are described. In an embodiment, Host Gesture Capture (HGC) logic detects a gesture in response to a touch event. The HGC logic forwards the gesture to Host Gesture Emulator (HGE) logic in response to a determination that the gesture is unrelated to an operation of a host system. The HGE logic operates in accordance with a guest operating system of the host system. Other embodiments are also claimed and described.

Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.